BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30925338)

  • 1. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
    Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
    Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
    Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.
    Neumann T; Benajiba L; Göring S; Stegmaier K; Schmidt B
    J Med Chem; 2015 Nov; 58(22):8907-19. PubMed ID: 26496242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.
    Oukoloff K; Coquelle N; Bartolini M; Naldi M; Le Guevel R; Bach S; Josselin B; Ruchaud S; Catto M; Pisani L; Denora N; Iacobazzi RM; Silman I; Sussman JL; Buron F; Colletier JP; Jean L; Routier S; Renard PY
    Eur J Med Chem; 2019 Apr; 168():58-77. PubMed ID: 30798053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
    Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.
    Banerji V; Frumm SM; Ross KN; Li LS; Schinzel AC; Hahn CK; Kakoza RM; Chow KT; Ross L; Alexe G; Tolliday N; Inguilizian H; Galinsky I; Stone RM; DeAngelo DJ; Roti G; Aster JC; Hahn WC; Kung AL; Stegmaier K
    J Clin Invest; 2012 Mar; 122(3):935-47. PubMed ID: 22326953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.
    Winfield HJ; Cahill MM; O'Shea KD; Pierce LT; Robert T; Ruchaud S; Bach S; Marchand P; McCarthy FO
    Bioorg Med Chem; 2018 Aug; 26(14):4209-4224. PubMed ID: 30026041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
    Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
    Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.
    Hu S; Ueda M; Stetson L; Ignatz-Hoover J; Moreton S; Chakrabarti A; Xia Z; Karan G; de Lima M; Agrawal MK; Wald DN
    Mol Cancer Ther; 2016 Jul; 15(7):1485-1494. PubMed ID: 27196775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
    Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
    Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
    Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors.
    Zhou Y; Zhang L; Fu X; Jiang Z; Tong R; Shi J; Li J; Zhong L
    Chem Biodivers; 2019 Sep; 16(9):e1900304. PubMed ID: 31338947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study.
    Guo J; Zhu M; Wu T; Hao C; Wang K; Yan Z; Huang W; Wang J; Zhao D; Cheng M
    Bioorg Med Chem; 2017 Jul; 25(13):3500-3511. PubMed ID: 28502459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates.
    Khan I; Tantray MA; Hamid H; Sarwar Alam M; Sharma K; Kesharwani P
    Bioorg Chem; 2022 Feb; 119():105512. PubMed ID: 34861627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
    Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
    Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
    Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
    J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
    La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
    J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.